{"groups":[{"description":"For patients who are \\< 60 years.\n\n* Melphalan: 140 mg/m2/day IV on Day: -6\n* Fludarabine: 40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance (CrCl) may be estimated by the Cockcroft Formula: CrCl = \\[(140-age) x weight (kg) x 0.85 (for women only)\\]/ \\[72 x creat (mg/dl)\\].)\n* TBI: 200 cGy Day: -1.\n\nFor patients who are ≥60 years and/or Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score of \\>3 (at the discretion of treating physician will have an option to receive):\n\n* Melphalan: 70 mg/m2/day IV on Day -6.\n* Fludarabine: 40 mg/m2/day IV Days -5, -4, -3, -2.\n* TBI: 200 cGy; Days -1.\n\nEvomela: 140 mg/m\\^2/day IV on Day -6 for patients who are \\< 60 years of age. 70 mg/m\\^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of \\>3\n\nFludarabine: 40 mg/ m\\^2/day intravenous on Days: -5 -4, -3, -2\n\nTotal Body Irradiation: 200 cGy on Day: -1","id":"FG000","title":"MEL/FLU and Total-Body Irradiation (TBI)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}